Kymera reports ~$560M cash, 2023 pipeline goals including KT-474 Phase 2 start with Sanofi

Kymera Therapeutics, Inc.

Preliminary cash, cash equivalents and investments of ~$560M as of Dec 31, 2022, runway into H2 2025.
KT-474 (IRAK4 degrader) Phase 2 trials in HS and AD to initiate in 2023 in collaboration with Sanofi.
KT-333 (STAT3) Phase 1 dose escalation ongoing; 66% mean STAT3 degradation in PBMC at first dose level.
KT-413 (IRAKIMiD) Phase 1 completed two dose levels; dose-dependent degradation of IRAK4, Ikaros, Aiolos; no DLTs.
KT-253 (MDM2) IND cleared; Phase 1a to start Q1 2023 in solid tumors and hematological malignancies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.